Latest Breaking News On - Anders cervin - Page 1 : comparemela.com

Lyra Therapeutics (LYRA) Reports Positive Data from LANTERN Phase 2 Study of LYR-210

Lyra Therapeutics (LYRA) Reports Positive Data from LANTERN Phase 2 Study of LYR-210
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRobert kernAnders cervinCentre for clinical researchLyra therapeutics incAmerican rhinologic societyWall streetOtolaryngology spring meetingsProfessor chairClinical researchRoyal brisbaneHospital campusQueensland australiaChief medical officerAmerican rhinologicMental component summary

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

/PRNewswire/ Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,.

United statesRobert kernAnders cervinKathryn morrisCentre for clinical researchLyra therapeutics incAmerican rhinologic societyLyra therapeuticsOtolaryngology spring meetingsProfessor chairClinical researchRoyal brisbaneHospital campusQueensland australiaChief medical officerAmerican rhinologic

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022

Lyra Therapeutics Presents Positive Data from LANTERN Phase 2 Study of LYR-210 for Treatment of Chronic Rhinosinusitis at COSM 2022
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesRobert kernAnders cervinKathryn morrisCentre for clinical researchLyra therapeutics incAmerican rhinologic societyLyra therapeuticsOtolaryngology spring meetingsProfessor chairClinical researchRoyal brisbaneHospital campusQueensland australiaChief medical officerAmerican rhinologic

Lyra Therapeutics Announces First Patient Treated in Phase 2 BEACON Clinical Trial of LYR-220 in Post-Surgical Chronic Rhinosinusitis Patients

/PRNewswire/ Lyra Therapeutics, Inc. (NASDAQ: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,.

Anders cervinKathryn morrisMaria palasisCentre for clinical researchPrnewswire lyra therapeutics incLyra therapeutics incProfessor chairClinical researchRoyal brisbaneHospital campusPrincipal investigatorChief executive officerPrivate securities litigation reform actAnnual reportLyra therapeutics

Lyra Therapeutics Announces Two Presentations at Upcoming COSM 2022

/PRNewswire/ Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,.

United statesAnders cervinKathryn morrisPrnewswire lyra therapeutics incLyra therapeutics incAmerican rhinologic societyLong acting implantable corticosteroid matricesTop clinicalPresentations demonstrate potential benefitChronic rhinosinusitisOtolaryngology spring meetingsTop rated abstractsOral presentationPatient perceptionsPrivate securities litigation reform actAnnual report